icad inc (ICAD) - Net Assets
Based on the latest financial reports, icad inc (ICAD) has net assets worth $30.79 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($39.47 Million) and total liabilities ($8.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check icad inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $30.79 Million |
| % of Total Assets | 78.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | -6.03% |
| 10-Year Change | -12.4% |
| Growth Volatility | 181.5 |
icad inc - Net Assets Trend (1987–2024)
This chart illustrates how icad inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is icad inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for icad inc (1987–2024)
The table below shows the annual net assets of icad inc from 1987 to 2024. For live valuation and market cap data, see ICAD market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $28.68 Million | -14.16% |
| 2023-12-31 | $33.42 Million | -4.25% |
| 2022-12-31 | $34.90 Million | -24.97% |
| 2021-12-31 | $46.52 Million | +52.39% |
| 2020-12-31 | $30.52 Million | +501.95% |
| 2019-12-31 | $5.07 Million | -26.46% |
| 2018-12-31 | $6.90 Million | -51.70% |
| 2017-12-31 | $14.28 Million | -42.98% |
| 2016-12-31 | $25.04 Million | -23.54% |
| 2015-12-31 | $32.75 Million | -47.84% |
| 2014-12-31 | $62.78 Million | +193.68% |
| 2013-12-31 | $21.38 Million | -22.73% |
| 2012-12-31 | $27.66 Million | -23.27% |
| 2011-12-31 | $36.05 Million | -50.75% |
| 2010-12-31 | $73.21 Million | +10.41% |
| 2009-12-31 | $66.31 Million | +0.02% |
| 2008-12-31 | $66.29 Million | +35.71% |
| 2007-12-31 | $48.85 Million | +1.83% |
| 2006-12-31 | $47.97 Million | -9.02% |
| 2005-12-31 | $52.73 Million | -7.45% |
| 2004-12-31 | $56.97 Million | +18.95% |
| 2003-12-31 | $47.90 Million | +123.23% |
| 2002-12-31 | $21.46 Million | +951.96% |
| 2001-12-31 | $2.04 Million | -29.72% |
| 2000-12-31 | $2.90 Million | -3.26% |
| 1999-12-31 | $3.00 Million | +30.43% |
| 1998-12-31 | $2.30 Million | -32.35% |
| 1997-12-31 | $3.40 Million | -17.07% |
| 1996-12-31 | $4.10 Million | -51.76% |
| 1995-12-31 | $8.50 Million | -37.50% |
| 1994-12-31 | $13.60 Million | +8.80% |
| 1993-12-31 | $12.50 Million | -1.57% |
| 1992-12-31 | $12.70 Million | +54.88% |
| 1991-12-31 | $8.20 Million | -37.40% |
| 1990-12-31 | $13.10 Million | -14.38% |
| 1989-12-31 | $15.30 Million | +93.67% |
| 1988-12-31 | $7.90 Million | +325.71% |
| 1987-12-31 | $-3.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to icad inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26019900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $265.00K | 0.92% |
| Other Components | $305.72 Million | 1065.81% |
| Total Equity | $28.68 Million | 100.00% |
icad inc Competitors by Market Cap
The table below lists competitors of icad inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dmc Global Inc
NASDAQ:BOOM
|
$106.32 Million |
|
Avadh Sugar & Energy Limited
NSE:AVADHSUGAR
|
$106.36 Million |
|
TCM Group
CO:TCM
|
$106.36 Million |
|
Kimlun Corporation Bhd
KLSE:5171
|
$106.37 Million |
|
Yi Jinn Industrial Co Ltd
TW:1457
|
$106.31 Million |
|
Energy World Corporation Ltd
AU:EWC
|
$106.29 Million |
|
GSD Holding AS
IS:GSDHO
|
$106.23 Million |
|
Michael Hill International Ltd
AU:MHJ
|
$106.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in icad inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 33,417,000 to 28,684,000, a change of -4,733,000 (-14.2%).
- Net loss of 5,616,000 reduced equity.
- Other factors increased equity by 883,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.62 Million | -19.58% |
| Other Changes | $883.00K | +3.08% |
| Total Change | $- | -14.16% |
Book Value vs Market Value Analysis
This analysis compares icad inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.56x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1987-12-31 | $-3.34 | $3.87 | x |
| 1988-12-31 | $6.56 | $3.87 | x |
| 1989-12-31 | $10.93 | $3.87 | x |
| 1990-12-31 | $8.83 | $3.87 | x |
| 1991-12-31 | $5.49 | $3.87 | x |
| 1992-12-31 | $8.19 | $3.87 | x |
| 1993-12-31 | $7.81 | $3.87 | x |
| 1994-12-31 | $8.31 | $3.87 | x |
| 1995-12-31 | $5.36 | $3.87 | x |
| 1996-12-31 | $2.55 | $3.87 | x |
| 1997-12-31 | $1.70 | $3.87 | x |
| 1998-12-31 | $1.13 | $3.87 | x |
| 1999-12-31 | $1.18 | $3.87 | x |
| 2000-12-31 | $1.09 | $3.87 | x |
| 2001-12-31 | $0.73 | $3.87 | x |
| 2002-12-31 | $5.13 | $3.87 | x |
| 2003-12-31 | $8.88 | $3.87 | x |
| 2004-12-31 | $8.36 | $3.87 | x |
| 2005-12-31 | $7.20 | $3.87 | x |
| 2006-12-31 | $6.50 | $3.87 | x |
| 2007-12-31 | $6.37 | $3.87 | x |
| 2008-12-31 | $7.75 | $3.87 | x |
| 2009-12-31 | $7.28 | $3.87 | x |
| 2010-12-31 | $7.99 | $3.87 | x |
| 2011-12-31 | $3.30 | $3.87 | x |
| 2012-12-31 | $2.56 | $3.87 | x |
| 2013-12-31 | $1.97 | $3.87 | x |
| 2014-12-31 | $4.45 | $3.87 | x |
| 2015-12-31 | $2.09 | $3.87 | x |
| 2016-12-31 | $1.57 | $3.87 | x |
| 2017-12-31 | $0.87 | $3.87 | x |
| 2018-12-31 | $0.41 | $3.87 | x |
| 2019-12-31 | $0.28 | $3.87 | x |
| 2020-12-31 | $1.38 | $3.87 | x |
| 2021-12-31 | $1.88 | $3.87 | x |
| 2022-12-31 | $1.38 | $3.87 | x |
| 2023-12-31 | $1.30 | $3.87 | x |
| 2024-12-31 | $1.09 | $3.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently icad inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -28.64%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.31x
- Recent ROE (-19.58%) is above the historical average (-50.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1987 | 0.00% | -318.52% | 0.30x | 0.00x | $-8.25 Million |
| 1988 | -67.09% | -47.32% | 0.59x | 2.39x | $-6.09 Million |
| 1989 | -22.88% | -19.02% | 0.80x | 1.51x | $-5.03 Million |
| 1990 | -17.56% | -10.60% | 0.99x | 1.67x | $-3.61 Million |
| 1991 | -60.98% | -42.02% | 0.79x | 1.84x | $-5.82 Million |
| 1992 | 29.92% | 16.52% | 1.17x | 1.54x | $2.53 Million |
| 1993 | -6.40% | -3.88% | 1.14x | 1.45x | $-2.05 Million |
| 1994 | 6.62% | 3.69% | 1.13x | 1.59x | $-460.00K |
| 1995 | -62.35% | -25.73% | 1.11x | 2.18x | $-6.15 Million |
| 1996 | -148.78% | -53.98% | 0.88x | 3.12x | $-6.51 Million |
| 1997 | -23.53% | -10.13% | 1.11x | 2.09x | $-1.14 Million |
| 1998 | -147.83% | -64.15% | 0.83x | 2.78x | $-3.63 Million |
| 1999 | -133.33% | -59.70% | 1.18x | 1.90x | $-4.30 Million |
| 2000 | -62.98% | -23.45% | 1.31x | 2.05x | $-2.12 Million |
| 2001 | -128.50% | -54.20% | 1.16x | 2.04x | $-2.82 Million |
| 2002 | -43.90% | -188.36% | 0.19x | 1.22x | $-11.56 Million |
| 2003 | -17.12% | -125.74% | 0.10x | 1.31x | $-12.99 Million |
| 2004 | -1.45% | -3.55% | 0.36x | 1.14x | $-6.53 Million |
| 2005 | -9.02% | -24.07% | 0.32x | 1.17x | $-10.03 Million |
| 2006 | -13.84% | -33.66% | 0.33x | 1.26x | $-11.44 Million |
| 2007 | -3.15% | -5.78% | 0.43x | 1.26x | $-6.42 Million |
| 2008 | 6.57% | 11.62% | 0.51x | 1.10x | $-2.27 Million |
| 2009 | -2.97% | -7.00% | 0.38x | 1.11x | $-8.60 Million |
| 2010 | -8.50% | -25.33% | 0.26x | 1.28x | $-13.54 Million |
| 2011 | -104.25% | -131.18% | 0.55x | 1.44x | $-41.19 Million |
| 2012 | -33.88% | -33.15% | 0.47x | 2.17x | $-12.14 Million |
| 2013 | -35.59% | -23.01% | 0.56x | 2.76x | $-9.75 Million |
| 2014 | -1.61% | -2.30% | 0.47x | 1.49x | $-7.29 Million |
| 2015 | -99.09% | -78.08% | 0.85x | 1.49x | $-35.72 Million |
| 2016 | -40.33% | -38.34% | 0.68x | 1.54x | $-12.60 Million |
| 2017 | -99.86% | -50.73% | 0.87x | 2.25x | $-15.68 Million |
| 2018 | -130.76% | -35.19% | 0.81x | 4.60x | $-9.71 Million |
| 2019 | -267.23% | -43.24% | 0.75x | 8.23x | $-14.06 Million |
| 2020 | -57.69% | -59.30% | 0.53x | 1.82x | $-20.66 Million |
| 2021 | -24.17% | -33.43% | 0.54x | 1.34x | $-15.90 Million |
| 2022 | -39.13% | -48.87% | 0.54x | 1.48x | $-17.15 Million |
| 2023 | -14.50% | -27.99% | 0.42x | 1.24x | $-8.19 Million |
| 2024 | -19.58% | -28.64% | 0.52x | 1.31x | $-8.48 Million |
Industry Comparison
This section compares icad inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| icad inc (ICAD) | $30.79 Million | 0.00% | 0.28x | $106.31 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About icad inc
iCAD, Inc. provides AI-powered cancer detection solutions in the United States. The company's ProFound Breast Health Suite offers solutions for"breast"cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications; and enables medical providers and professionals to accurat… Read more